Research
Molecular
BGM1812 is a novel dual amylin and calcitonin receptor agonist with enhanced efficacy compared to petrelintide.
BGM1812 may be a promising option for obesity treatment.
StrongSupportsmedium confidence
In both in vivo and in vitro studies, BGM1812 showed significantly enhanced efficacy.
Why this rating
The study involves in vivo and in vitro research, indicating strong evidence.
Source
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Leilei Zong et al. · Journal of Medicinal Chemistry · 2025
otherCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →